Literature DB >> 29082525

Dynamics of neutrophil gelatinase-associated lipocalin plasma and cerebrospinal fluid concentrations in older males.

Petrus J W Naudé1,2, Doortje W Dekens1,2, Ulrich L M Eisel2,3, Izaak den Daas4, Peter P De Deyn1,5.   

Abstract

BACKGROUND: Neutrophil gelatinase-associated lipocalin (NGAL) is an inflammatory protein with gaining increasing interest for its use as marker in blood and cerebrospinal fluid (CSF) for several chronic diseases. Its biochemical properties make it an attractive marker. However, changes in blood and CSF NGAL concentrations during the diurnal rhythm in the elderly are unknown. This information is important for its optimal use as marker in studies with older people.
METHODS: Serial paired plasma and CSF samples were obtained from 8 healthy elderly males over a 30-hour period. NGAL and cortisol were quantified with ELISA.
RESULTS: No significant changes in plasma and CSF NGAL concentrations over time were found, whereas cortisol (included as internal control) concentrations displayed significant changes over time. Significant circadian patterns were found for plasma NGAL and for cortisol in both plasma and CSF. However, CSF NGAL concentrations did not follow a diurnal pattern in elderly males.
CONCLUSIONS: This study illustrates the temporal regulation of NGAL in plasma and CSF, which potentially is a useful reference for studies measuring NGAL as biomarker in older individuals.
© 2017 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  cerebrospinal fluid; circadian rhythm; cortisol; lipocalin 2; repeated measures

Mesh:

Substances:

Year:  2017        PMID: 29082525     DOI: 10.1111/eci.12853

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  1 in total

1.  Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy.

Authors:  A Matet; T Jaworski; E Bousquet; J Canonica; C Gobeaux; A Daruich; M Zhao; M Zola; M Meester-Smoor; D Mohabati; F Jaisser; S Yzer; F Behar-Cohen
Journal:  Sci Rep       Date:  2020-11-19       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.